These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26434857)

  • 1. Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases.
    Masroor M; Mir R; Javid J; Prasant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
    Asian Pac J Cancer Prev; 2015; 16(15):6445-9. PubMed ID: 26434857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients.
    Ali Beg MM; Fahdil SR; Yadav P; Shukla KK; Mohan A; Saxena A
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):825-830. PubMed ID: 30912007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
    Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
    Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.
    Mohan A; Ansari A; Masroor M; Saxena A; Pandey RM; Upadhyay A; Luthra K; Khilnani GC; Jain D; Kumar R; Guleria R
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3153-3163. PubMed ID: 33247670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
    Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
    Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
    Yin H; Liao CG; Wang YQ; Li Z; Fan LL; Qian ML; Lu N
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):419-423. PubMed ID: 28635230
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
    Hong SH; An HJ; Kim K; Lee SS; Lee YG; Yuh YJ; Park IC; Chae YS; Jang TW; Kang JH
    Oncology; 2019; 96(1):51-58. PubMed ID: 30368503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of mutations in epidermal growth factor receptor gene on growth, metastasis and survival rate of non-small cell lung carcinoma].
    Yin XW; Jiang XT; Yuan YT; Du YP
    Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(26):1808-12. PubMed ID: 20979823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
    Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
    Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
    Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
    Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia.
    Sutandyo N; Suratman E
    Acta Med Indones; 2018 Oct; 50(4):291-298. PubMed ID: 30630993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
    Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
    Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.